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Introduction:  FacioScapuloHumeral  Muscular  Dystrophy  (FSHD),  a  disease  linked  to  a  heterozygous  D4Z4
deletion  on  chromosome  4q35,  typically  starts  with  shoulder-girdle  and  facial  muscle  involvement.
Atypical  presentations  have  occasionally  been  reported,  but their  frequency  has  still  not been  deﬁned.
Patients  and  methods:  We  studied  the  occurrence  rate  of  FSHD  with  atypical  onset  in  122 symptomatic
subjects  from  76 unrelated  families  with  genetically  conﬁrmed  FSHD.  These  75  males  and  47  females,
with  a mean  age of 49  years  (range:  11–85),  had  a mean  EcoRI  fragment  of  25  kb  (range:  11–38).
Results:  Typical  shoulder-girdle  or facial  weakness  at onset  was  reported  by 88  patients  (72%).  Unusual
presentations  included:  foot  drop  in  16 (13%)  and  proximal  lower  limb  weakness  in  eight  patients  (7%).
Two  cases  at  onset  manifested  quite  atypical,  apparently  non-FSHD-related  syndromes:  a  42-year-oldyoglobinuria
alpain
woman  presented  with  infantile  epilepsy  and  a 41-year-old  man  with  myoglobinuria.  In  the  latter  patient,
DNA analysis  detected  a 4q35  deletion  associated  to an  heterozygous  CAPN3  mutation.
Conclusion:  FSHD  presentation  with  foot  drop  or lower  limb  proximal  weakness  appeared  to  be  more
frequent  than  expected.  This  type  of weakness  at onset  has  to  be considered  premature,  but still  rep-
resentative  of  disease-related  muscle  involvement.  Quite  atypical  onset  appears  very rare  and  calls  for
further  investigation  on  non-FSHD-related  etiology.. Introduction
In Western countries, FacioScapuloHumeral Muscular Dystro-
hy (FSHD) has a prevalence rate of about 4–5 × 10−5, making it
ne of the most frequent hereditary muscle disorders [1–3]. For
his autosomal dominant disease, whose locus is on chromosome
q35, genetic studies have deﬁned a characteristic deletion of the
4Z4 3.3 kb tandem repeat on EcoRI digested DNA, with a residual
ragment of 10–38 kb [3–5]. On clinical grounds, current and histor-
cal reviews [3,6,22–24] indicate that FSHD generally starts during
dolescence and the presenting symptoms are typically variable
egrees of muscle weakness, involving the facial and shoulder-
irdle muscles. In genetically conﬁrmed FSHD patients, clinical
resentation with foot drop has occasionally been described [7,8],
ut its frequency has still not been determined. In 2000, van der
ooi et al. [7] reported atypical disease onsets characterized by
eakness in the posterior leg compartment or proximal lower limb
uscles. These types of presentation were subsequently conﬁrmed
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by others [8–10]. Congenital extraocular muscle weakness, a more
unexpected disease onset, was observed in three FSHD cases from
the same family only by Krasnianski et al. [11].
The aim of our investigation was to identify the rate of occur-
rence and the clinical features of non-typical versus typical disease
onsets in a series of 122 FSHD cases, belonging to 76 unrelated
families with genetically conﬁrmed diagnosis.
2. Patients and methods
2.1. General clinical data
Our investigation was carried out as a collaborative study
involving the Neuromuscular Centre of the Department of Neu-
rosciences of the University of Padua and the Clinical Centre for
Neuromuscular Diseases of UILDM, the Muscular Dystrophy Asso-
ciation of Padua. Our cohort of cases with a molecular diagnosis of
FSHD included 156 consecutive subjects, belonging to 76 unrelated
families. Of these individuals, 122 were symptomatic, whereas 34
manifested no signs or symptoms of the disease. Our study included
Open access under CC BY-NC-ND license.only the symptomatic cases. These 122 patients consisted of 76
index cases and 46 additional symptomatic subjects, who  were
identiﬁed by a thorough clinical and molecular investigation of
family members. In the index cases, FSHD was  deﬁned according
y and Neurosurgery 114 (2012) 230– 234 231
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Table 2
FSHD clinical onset: the predominant types.a
Facio-scapulo-humeral onset
Scapulo-humeral symptoms 80/122
M/F  56/24
Age at onset 24 years (range: 5–60)
Unilateral 32/80
Bilateral 48/80
Signs of facial weakness 78/80
Eco RI fragment (mean) 24 kb (range: 14–38)
Facial symptoms 8/122
M/F  3/5
Age at onset 8 (range: 4–23)
Signs of scapulo-humeral weakness 8/8
Eco RI fragment (mean) 18 kb (range: 14–30)
Foot drop onset 16/122
M/F 9/7
Age at onset 27 (range: 10–53)
Unilateral 12/16
Bilateral 4/16
Signs of scapulo-humeral weakness 14/16
Signs of facial weakness 15/16
symptoms by 88 of our 122 symptomatic FSHD patients (72%).
In seven cases (Table 3), the disease showed a late-onset pre-
sentation at a mean age of 39, with shoulder-girdle weakness in
Table 3
Some data of 18 FSHD patients with non-typical onset.
Facial-sparinga: 7 cases
M/F  5/2
Present age 63 (range: 44–79)E. Pastorello et al. / Clinical Neurolog
o the European Neuromuscular Consortium criteria including evi-
ence of myopathy at muscle biopsy, in the absence of features
ndicative of alternative diagnosis [12]. Determination of the 4q35
4Z4 deletion on EcoRI digested DNA, extracted from peripheral
lood, was carried out as previously reported [13–15].
As shown in Table 1, the 122 symptomatic cases comprised 75
ales and 47 females with a mean age of 49 years (range: 11–85).
n these patients, the mean EcoRI fragment detected by molecular
nalysis was 25 kb in length (range: 11–38 kb).
.2. Disease onset
All 122 symptomatic patients were evaluated by a clinical ques-
ionnaire focusing on ﬁrst clinical disturbance manifested by the
atient and age of onset. To avoid potential patient bias, the patient
r relatives answered the questionnaire with the assistance of one
f the clinicians involved in this investigation. Either the patient’s
wn recollection of initial symptoms or the ﬁrst clinical abnormal-
ty observed by relatives, as in the case of children or patients’
iblings, were considered signiﬁcant. The record of each subject’
rst neuromuscular examination was reviewed in order to have
n objective description of early overall muscle weakness. Mus-
le groups were deﬁned by their topographical distribution: face,
pper or lower girdle, upper or lower limbs, with an additional
istinction between proximal or distal compartments.
Early extra-muscular symptoms or signs of hearing, visual,
erebral, or cardiac involvement were also sought. This part of
ur investigation was planned due to the occasional symptoms
eported by FSHD patients, related to auditory impairment, visual
bnormalities, mental retardation, epilepsy or heart arrhythmias
15–20].
. Results
Mean age at onset in our unselected series of 122 FSHD patients
as 23 years, with a wide range from childhood to adulthood
Table 1). When the 76 index cases were considered separately from
heir 46 affected relatives, mean age at onset was  21 years (range:
–60). Instead, in affected relatives it was 26 years (range: 9–56).
As shown in Table 2, scapulo-humeral muscle weakness was
eported at onset in 80 out of 122 cases. In all, associated signs
f facial weakness were clearly demonstrable at initial neuromus-
ular examination. Weakness was asymmetrical in 32 of these 80
ases (40%). Their mean EcoRI fragment was 24 kb, ranging from 14
able 1
eneral clinical data of the 122 FSHD subjects considered in the study.c
Number of patients 122
Index cases 76
Symptomatic relatives 46
Male/female 75/47
Present age (mean) 49 years (range: 11–85)
Eco RI fragment (mean) 25 kb (range: 11–38)
Age  at onset (mean) 23 years (range: 4–60)
Type of clinical onset
Typicala 72%
Scapulo-humeral 80/122
Facial 8/122
Non-typicala 28%
Facial-sparingb 7/122 (6%)
Foot drop 16/122(13%)
Proximal lower limbs 8/122 (7%)
Other 3/122 (2%)
a Typical or non-typical onset according to the FSHD diagnostic criteria of the
uropean Neuromuscular Centre (Ref. [12]).
b Cases which maintained the “facial-sparing” phenotype during the disease
ourse.
c The table summarizes all the different FSHD onset types observed in our 122
ases.Eco RI fragment (mean) 27 kb (range: 19–38)
a The onset type represented in the table concerns 104 out of 122 patients
to 38. In only eight cases (7%), facial weakness was the predomi-
nant clinical manifestation at onset. However, when ﬁrst examined,
all these patients also showed variable degrees of weakness in the
scapulo-humeral region. Their EcoRI fragment had a mean value
of 18 kb (range: 14–30). Altogether, disturbances related to facial
or scapulo-humeral weakness, which are the typical onset disor-
ders according to the FSHD diagnostic criteria of the European
Neuromuscular Centre [12], were reported to be the presentingAge at onset 39 (range: 22–59)
Signs of scapulo-humeral weakness 7/7
Eco RI fragment 36 kb (range: 32–38)
Lower limbs proximal weakness: 8 cases
M/F  0/8
Present age 59 (range: 34–78)
Age at onset 36 (range: 15–64)
Unilateral 0/8
Bilateral 8/8
Signs of scapulo-humeral weakness 8/8
Signs of facial weakness 8/8
Eco RI fragment (mean) 22 kb (range: 15–27)
Other types of onset
(3 cases):
Case 1 Case 2 Case 3b
Apparent onset type: Sural triceps
weakness
Epilepsy and
mental retardation
Myoglobinuria
Age at onset 21 years Infancy 18 years
Scapulo-humeral
weakness
−−−  ++− −−−
Facial weakness −−− +++ −−−
EcoRI 38 kb 11 kb 24 kb
Present age 43 years 42 years 41 years
cFSHD weakness scale
Present grade I IV IV
a Persistent “facial-sparing” phenotype during disease course.
b In this patient heterozygous CAPN3 mutation was associated with the 4q35
deletion.
c As previously described [18], the FSHD Weakness Scale ranges from 0 (no weak-
ness) to VII (maximal weakness).
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he absence of facial involvement. This “facial-sparing” phenotype
ppeared persistent over a mean disease course of 24 years. In
hese patients the EcoRI fragment size (mean value 36 kb, range:
2–38 kb) indicated a very small 4q35 deletion.
Foot drop was recollected as the ﬁrst clinical symptom by 16 of
ur 122 cases (13%), mostly unilaterally (12/16 cases: see Table 2).
his type of onset was only experienced by index cases (9 males
nd 7 females), with a mean age at onset of 27 years (range: 10–53).
oreover, at ﬁrst neurological evaluation scapulo-humeral or facial
eakness was detected in all but one index case. The EcoRI frag-
ent in these patients had a mean value of 27 kb (range: 19–38).
Onset with atypical proximal weakness in the lower limb mus-
les was reported by eight patients (7%), as shown in Table 3. They
ere all females with a mean age at onset of 36 years (range:
5–64). All were index cases, mostly with bilateral weakness of
he quadriceps muscle and less involvement of the iliopsoas. At
rst neurological examination, associated weakness in the scapulo-
umeral muscle region was identiﬁed in all of them. Likewise, all
howed variable facial muscle deﬁcit. In these eight cases, the 4q35
ragment ranged from 15 to 27 kb (mean 22 kb).
Clinical presentation with unilateral sural triceps involvement
as evident in only one of our FSHD subjects. The clinical features
f this 43-year-old man  are listed in Table 3 (case 1). Since age
1, he had difﬁcult walking on tip-toes and standing on his left leg.
ince the disturbance was associated with altered serum CK (three-
old the normal value) he was referred to our outpatient clinic for
eurological evaluation. His neuromuscular examination showed
oderate left leg triceps weakness and hypotrophy without other
bnormalities. His fraternal twin brother, who had already been
iagnosed elsewhere with FSHD, showed moderate weakness of
he scapulo-humeral muscles; he had complained of these distur-
ances since adolescence. Evaluation of the EcoRI fragment (38 kb)
evealed a small 4q35 deletion in both brothers.
Quite atypical onsets were reported by two FSHD subjects. The
rst (cases 2, Table 3) was a 42-year-old woman, whose mother suf-
ered from a mild form of FSHD myopathy and rare sporadic grand
al  seizures. The patient had long been considered affected by an
diopathic encephalopathy. She had been treated with antiepileptic
rugs since her ﬁrst year of life due to tonic or tonic–clonic seizures.
oreover, her psychomotor development was delayed, with ability
o walk at three and to speak a few words at ﬁve years of age. There
ere no evident causes of brain pathology either in the clinical his-ory (pregnancy and perinatal period uneventful) or from analysis
f her karyotype (no chromosomal abnormalities). Her IQ score was
.36 at 16 and 0.34 at 38 years of age. Interictal EEG ﬁndings were
ormal, aside from a few occasions (at 7, 15 and 35 years) when
able 4
ype of disease onset: comparison of our study with the two reports on FSHD series of ca
Series of cases Butz et al.c [10] 
General data
Number of cases 34 (from 39c) 
M/F 26/13 
Mean  age (range) 46 years (18–75) 
Onset  typea
Typical b (facial or scapulo-humeral) 24 cases (71%) (22 cases: 32–41 kb) (2 c
Facial-sparingd (scapulo-humeral) 6 cases (18%) (32–41 kb) 
Tibialis anterior (foot-drop) Not evaluated 
Proximal  lower limbs 2 cases (6%) (35 kb) 
Non-progressive pectoralis’ atrophia 2 cases (6%) (35–41 kb) 
Sural  triceps – 
Progressive Ext. ophthalmoplegia – 
Myoglobinuria –
Brain  involvement – 
a Muscles or tissues involved are indicated (in brackets the EcoRI fragment kb).
b Typical onset according to the FSHD diagnostic criteria of the European Neuromuscul
c 39 cases were re-examined in this series: 34 were conﬁrmed as FSHD, 5 were classiﬁ
d Persistent “facial-sparing” phenotype during disease course. Neurosurgery 114 (2012) 230– 234
brief diffuse discharges of spikes and polyspikes were detected. At
38, her brain MRI  was normal. Hearing loss had also appeared in
early childhood. Some facial weakness was evident before age ﬁve,
while difﬁculty in arm abduction and other signs of shoulder-girdle
muscle weakness had appeared at age 14. At present, she walks
independently with a mixed stepping and waddling gait and can
abduct her arms by 70◦. Facial weakness and mild bilateral foot
drop are also evident. Analysis of her DNA identiﬁed a 4q35 frag-
ment of 11 kb. Some clinical details of this case have been described
in a previous report on the infantile variant of FSHD [25].
A myoglobinuric attack during adolescence characterized dis-
ease onset in a 41-year-old man  (cases 3, Table 3). At 18 years of
age, he suffered from acute rhabdomyolysis triggered by prolonged
muscle activity. Urinalysis indicated massive myoglobinuria. The
patient improved but clinical investigations failed to identify any
recognized cause of myoglobinuria, including infections, exposure
to drugs or toxic factors, trauma or inherited errors of metabolism.
After recovery, his neurological examination revealed only a
mild hypotrophy of the left leg muscles. Muscle biopsy showed
no glycogen or lipid storage and no evidence of mitochondrial
myopathy. Normal biochemistry of muscle phosphorylase, phos-
phofructokinase and carnitine-palmitoyl-transferase ruled out the
relative metabolic causes of myoglobinuria. Routine muscle his-
tology showed non-speciﬁc myopathic changes. In the following
years, immunoblot analyses of dystrophin, dysferlin, sarcoglycans,
caveolin yielded normal results. At 30 years of age, he devel-
oped impaired arm abduction, suggesting the diagnosis of FSHD.
His DNA examination conﬁrmed the clinical diagnosis revealing a
4q35 fragment of 24 kb, inherited from his asymptomatic father.
Since FSHD did not provide an adequate explanation for rhab-
domyolysis at onset, a complete molecular study of the calpain3
gene (CAPN3) was  also carried out in muscle DNA. The molecular
analysis, performed as elsewhere reported [21], revealed an het-
erozygous mutation in CAPN3 exon 4 (c.505C>T R169C), in addition
to the previously identiﬁed FSHD 4q35 deletion.
In all our patients with atypical onset, clinical heart examina-
tion and 24-h ECG Holter monitoring gave normal results. Previous
cardiologic assessment in the majority of the patients included in
the present investigation has been described earlier [18].
Table 4 compares the main ﬁndings of our clinical research with
those of two similar studies reported to date on series of FSHD cases
with 4q35 analysis [10,11]. In the ﬁrst, Butz et al. [10] re-evaluated
39 patients, conﬁrming the FSHD diagnosis in 34 with an EcoRI
fragment ranging from 32 to 41 kb; they searched among them
for possible non-typical FSHD phenotypes according to the FSHD
diagnostic criteria of the European Neuromuscular Centre [12]. The
ses with 4q35 analysis.
Krasnianski et al. [11] Present study
41 122
Not reported 75/47
Not reported 49 years (11–85)
ases: >41 kb) 35 cases (85%) (<35 kb) 88 (72%) (14–38 kb)
3 cases (7%)(30–34 kb) 7 cases (6%) (32–38 kb)
Not evaluated 16 cases (13%) (19–38 kb)
– 8 cases (7%) (15–27 kb)
– –
– 1 case (38 kb)
3 cases (7%) (20 kb) –
– 1 case (24 kb)
– 1 case (11 kb)
ar Centre (Ref. [12]).
ed as non-FSHD.
y and
a
t
l
k
t
4
t
s
d
i
t
a
a
i
t
c
a
i
c
f
p
t
s
s
c
i
v
3
o
[
p
d
t
y
t
g
–
f
p
a
h
c
a
m
a
c
d
p
l
4
D
i
u
t
i
r
o
c
[E. Pastorello et al. / Clinical Neurolog
im of Krasnianski et al.’s [11] clinical investigation was to analyze
he occurrence of atypical clinical presentations among 41 unse-
ected FSHD patients with an EcoRI fragment size lower than 35
b. Table 4 mainly underlines the divergent results yielded by the
hree investigations on the types of atypical presentation.
. Discussion
In the vast majority of our FSHD patients, the characteris-
ic symptoms at onset were related to muscle weakness in the
houlder-girdle and facial regions, in agreement with the classical
escription of the disease [22–24] and the two most recent stud-
es on series of FSHD cases with 4q35 analysis [10,11].  Accordingly,
he initial prominent clinical problem in these subjects was char-
cterized by a variable and often asymmetrical difﬁculty in arm
bduction. Early neurological examination revealed variable wast-
ng of the related muscles, including the serratus anterior, lower
rapezius, pectoralis major and scapular ﬁxators. An associated
haracteristic sign in most of the same cases was  facial weakness,
lthough patients were not always aware of this. In only a minor-
ty of our patients (7%) facial weakness was reported as the ﬁrst
linical manifestation: these were mostly children, in whom the
acial abnormality was noted by parents. As expected, in subjects
resenting with facial weakness, the ﬁrst neuromuscular evalua-
ion documented a variable degree of associated weakness in the
capulo-humeral region.
In our research, some cases presented with a late-onset “facial-
paring” phenotype, which was maintained during the clinical
ourse. This infrequent clinical manifestation of the disease, as orig-
nally reported by Felice and Moore [8],  appeared to be related to
ery small 4q35 deletions, with EcoRI fragments ranging from 30 to
8 kb. Similar correlations were also observed in the investigations
f large series of genetically evaluated cases reported by Butz et al.
10] and Krasnianski et al. [11]. These studies on non-typical FSHD
resentation are compared with ours in Table 4.
It is generally accepted that FSHD typically starts in the second
ecade of life [3,6,22–24].  However, our clinical study showed that
he mean age of disease presentation among index cases was  21–22
ears, with a wide variability in age at onset (4–60 years).
Foot drop is generally considered rare among the initial symp-
oms reported by FSHD patients. Conversely, we observed stepping
ait, often unilateral, in 13% of our series of cases, showing that
 when carefully investigated – foot drop is not an uncommon
eature of disease onset. This ﬁnding, however, should not be sur-
rising since the tibialis anterior muscle is often affected during the
dvanced course of the disease [3,6,22–24].  Only one of our patients
ad foot drop at presentation without facio-scapulo-humeral mus-
le involvement, as described by van der Kooi et al. [7] and Felice
nd Moore [8].
The atypical FSHD presentation characterized by lower girdle
uscle weakness was found in 7% of our patients. All of them
lso showed variable degrees of facial and shoulder-girdle mus-
le involvement. This FSHD onset type, which has been extensively
escribed by other authors [7,10,11], is not so unexpected because
elvic girdle muscle involvement is a common occurrence in the
ater stages of the disease. In our patients with this onset type, the
q35 deletion was similar to the one found in typical FSHD cases.
ifferently, the deletion was very small in the two patients stud-
ed by Butz et al. [10], with a residual fragment size of 35 kb. The
nusual FSHD clinical presentation with difﬁcult toe walking due
o unilateral triceps weakness was very rare in our series, involv-
ng only one FSHD subject. This type of onset has previously been
eported by other authors [7,9]. Overall, the main non-typical FSHD
nset includes weakness in distal or proximal lower limb mus-
les, which are generally involved at a later stage of the disease
3,6,22–24]. Neurosurgery 114 (2012) 230– 234 233
Seizures in early infancy, with associated delay in psychomo-
tor development, was  another atypical presentation among our
subjects. It was observed in a patient who had been considered
encephalopathic until her dystrophic symptoms became apparent
in adolescence. Epilepsy seems to be a phenotypic feature particu-
larly of the early onset FSHD variant, in which epilepsy and mental
retardation have been associated with 4q35 deletion fragment sizes
of 10–12 kb [6,25].
In  a young patient of ours, a puzzling disease onset was  repre-
sented by an acute episode of rhabdomyolysis with myoglobinuria.
This syndrome, that has occasionally been described in patients
with other type of muscular dystrophies (namely the ones deter-
mined by mutations in sarcolemma-related proteins [24]), has
never been reported in FSHD cases. After the peculiar onset,
our patient developed a typical FSHD, conﬁrmed by detection of
the characteristic 4q35 deletion (residual fragment 23 kb). Subse-
quently, however, a heterozygous mutation in the calpain 3 gene
(CAPN3) was  also identiﬁed in the same subject. Considering that
mild myopathy in this patient could be related to the heterozygous
CAPN3 mutation [21], acute myoglobinuria could also be attributed
to the second muscle disease.
Progressive external ophthalmoplegia, the uncharacteristic dis-
ease onset described in an FSHD family by Krasnianski et al. [11],
was  not observed in any of our patients. This unexpected disease
onset was reported in three siblings who  subsequently developed
an FSHD phenotype with evidence of the 4q35 deletion and no
mitochondrial myopathy.
5. Conclusion
On the whole, our study showed that non-typical FSHD presen-
tation with distal or proximal weakness in the lower limbs was
more frequent than expected. On the other hand, since lower limb
muscle weakness characterizes the advanced stages of the dis-
ease, observation at onset seems to constitute a premature rather
than an unrepresentative FSHD clinical feature. It also conﬁrms the
substantial homogeneity of overall muscle involvement in FSHD.
Quite atypical disease presentations are very rare and need further
research on concomitant non-FSHD-related etiological factors.
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